Shayne C Gad
Overview
Explore the profile of Shayne C Gad including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
328
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gad S, Sullivan Jr D, Pitts D
Int J Toxicol
. 2024 Sep;
43(6):520-539.
PMID: 39326876
This is the 12th in a series of salary surveys conducted at approximately 3-year intervals for toxicologists that began in 1988. Previous salary surveys were conducted in 1988, 1991, 1995,...
2.
Sullivan Jr D, Gad S
Int J Toxicol
. 2023 Mar;
42(4):309-325.
PMID: 36946501
This is the eleventh in a series of salary surveys for toxicologists conducted at three-year intervals that began in 1988. Previous salary surveys were conducted in 1988, 1991, 1995, 1998,...
3.
Johnson C, Ahlberg E, Anger L, Beilke L, Benigni R, Bercu J, et al.
Regul Toxicol Pharmacol
. 2020 Jul;
116:104688.
PMID: 32621976
The assessment of skin sensitization has evolved over the past few years to include in vitro assessments of key events along the adverse outcome pathway and opportunistically capitalize on the...
4.
Sullivan Jr D, Gad S
Int J Toxicol
. 2020 Mar;
39(3):189-197.
PMID: 32180480
This survey serves as the tenth in a series of toxicology salary surveys conducted at 3-year intervals and beginning in 1988. An electronic survey instrument was distributed to members of...
5.
Gad S, Sullivan Jr D, Mujer C, Spainhour C, Crapo J
Int J Toxicol
. 2019 Jul;
38(4):291-302.
PMID: 31333066
Since our earlier publication (Gad et al, 2013), BioMimetix has advanced BMX-010 (Manganese (III) meso-tetrakis(N-ethylpyridinium-2-yl)porphyrin or MnTE020PyP; CASRN 219818-60-7) into clinical development as a topical agent for the treatment of...
6.
Gad S, Schuh J
Toxicol Pathol
. 2018 Apr;
46(4):366-371.
PMID: 29683082
Safety ("biocompatibility") assessment of medical devices has evolved along a different path than that of drugs, being historically governed more by the considerations and needs of engineers rather than chemists...
7.
Elmore S, Aeffner F, Bangari D, Crabbs T, Fossey S, Gad S, et al.
Toxicol Pathol
. 2017 Nov;
45(7):799-833.
PMID: 29113559
The 2017 annual National Toxicology Program Satellite Symposium, entitled "Pathology Potpourri," was held in Montreal, Quebec, Canada at the Society of Toxicologic Pathology's 36th annual meeting. The goal of this...
8.
Stricker-Krongrad A, Shoemake C, Pereira M, Gad S, Brocksmith D, Bouchard G
Toxicol Pathol
. 2015 Dec;
44(3):421-7.
PMID: 26656239
The use of miniature swine as a nonrodent species in safety assessment has continued to expand for over a decade, and they are becoming routinely used in toxicology and in...
9.
Stern J, Kibanov Solomonov V, Sazykina E, Schwartz J, Gad S, Goodrich G
Int J Toxicol
. 2015 Aug;
35(1):38-46.
PMID: 26296672
To evaluate the clinical safety profile for the use of gold nanoshells in patients with human prostate cancer. This follows on the nonclinical safety assessment of the AuroShell particles reported...
10.
Sullivan Jr D, Gad S, Laulicht B, Bakhru S, Steiner S
Int J Toxicol
. 2015 Jun;
34(4):308-17.
PMID: 26079256
A new molecular entity, PER977 (di-arginine piperazine), is in clinical development as an anticoagulant reversal agent for new oral anticoagulants and heparins. The good laboratory practices (GLP)-compliant studies were conducted...